OK Biotech Salute del bilancio

Salute finanziaria criteri di controllo 6/6

OK Biotech ha un patrimonio netto totale di NT$2.5B e un debito totale di NT$420.2M, che porta il suo rapporto debito/patrimonio netto a 17%. Le sue attività totali e le sue passività totali sono rispettivamente NT$3.6B e NT$1.1B. L'EBIT di OK Biotech è NT$8.1M rendendo il suo rapporto di copertura degli interessi 24. Ha liquidità e investimenti a breve termine pari a NT$404.9M.

Informazioni chiave

17.0%

Rapporto debito/patrimonio netto

NT$420.16m

Debito

Indice di copertura degli interessi	24x
Contanti	NT$404.87m
Patrimonio netto	NT$2.47b
Totale passività	NT$1.08b
Totale attività	NT$3.55b

Aggiornamenti recenti sulla salute finanziaria

OK Biotech (TPE:4155) Has A Pretty Healthy Balance Sheet

Mar 17

Here's Why OK Biotech (TPE:4155) Can Manage Its Debt Responsibly

Dec 08

Recent updates

OK Biotech's (TWSE:4155) Shareholders Have More To Worry About Than Lackluster Earnings

Aug 20

OK Biotech Co., Ltd. (TPE:4155) Investors Should Think About This Before Buying It For Its Dividend

Apr 26

Is OK Biotech Co., Ltd.'s (TPE:4155) Recent Price Movement Underpinned By Its Weak Fundamentals?

Feb 15

A Look At OK Biotech's (TPE:4155) Share Price Returns

Jan 31

We Wouldn't Rely On OK Biotech's (TPE:4155) Statutory Earnings As A Guide

Jan 17

Consider This Before Buying OK Biotech Co., Ltd. (TPE:4155) For The 5.4% Dividend

Jan 03

Estimating The Intrinsic Value Of OK Biotech Co., Ltd. (TPE:4155)

Dec 21

Here's Why OK Biotech (TPE:4155) Can Manage Its Debt Responsibly

Dec 08

Should You Be Impressed By OK Biotech's (TPE:4155) Returns on Capital?

Nov 23

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( NT$1.5B ) di 4155 superano le sue passività a breve termine ( NT$866.1M ).

Passività a lungo termine: Le attività a breve termine di 4155 ( NT$1.5B ) superano le sue passività a lungo termine ( NT$213.0M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 0.6% ) di 4155 è considerato soddisfacente.

Riduzione del debito: Il rapporto debito/patrimonio netto di 4155 si è ridotto da 23.2% a 17% negli ultimi 5 anni.

Copertura del debito: Il debito di 4155 è ben coperto dal flusso di cassa operativo ( 42.6% ).

Copertura degli interessi: I pagamenti degli interessi sul debito di 4155 sono ben coperti dall'EBIT ( 24 x copertura).

OK Biotech Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

OK Biotech (TPE:4155) Has A Pretty Healthy Balance Sheet

Here's Why OK Biotech (TPE:4155) Can Manage Its Debt Responsibly

Recent updates

OK Biotech Co., Ltd. to Report Q3, 2024 Results on Nov 12, 2024

OK Biotech's (TWSE:4155) Shareholders Have More To Worry About Than Lackluster Earnings

Second quarter 2024 earnings released: EPS: NT$0.29 (vs NT$0.12 in 2Q 2023)

Dividend of NT$0.30 announced

Ok Biotech Co., Ltd. Announces Cash Dividend, Payable on September 27, 2024

OK Biotech Co., Ltd. to Report Q2, 2024 Results on Aug 09, 2024

OK Biotech Co., Ltd. Announces Change of Directors

First quarter 2024 earnings released: EPS: NT$0.25 (vs NT$0.16 in 1Q 2023)

OK Biotech Co., Ltd. to Report Q1, 2024 Results on May 10, 2024

Full year 2023 earnings released: EPS: NT$0.02 (vs NT$1.37 in FY 2022)

OK Biotech Co., Ltd., Annual General Meeting, May 29, 2024

New minor risk - Profit margin trend

New minor risk - Market cap size

Upcoming dividend of NT$1.23 per share at 3.8% yield

Second quarter 2023 earnings released: EPS: NT$0.13 (vs NT$0.57 in 2Q 2022)

New major risk - Dividend sustainability

New minor risk - Share price stability

Investor sentiment improves as stock rises 18%

Full year 2022 earnings released: EPS: NT$1.51 (vs NT$0.46 in FY 2021)

Third quarter 2022 earnings released: EPS: NT$0.49 (vs NT$0.16 in 3Q 2021)

Less than half of directors are independent

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: NT$0.57 (vs NT$0.002 loss in 2Q 2021)

Upcoming dividend of NT$1.00 per share

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Full year 2021 earnings: EPS and revenues miss analyst expectations

Now 21% undervalued after recent price drop

Third quarter 2021 earnings released: EPS NT$0.16 (vs NT$0.30 in 3Q 2020)

Second quarter 2021 earnings released: NT$0.002 loss per share (vs NT$0.27 profit in 2Q 2020)

Upcoming dividend of NT$1.39 per share

First quarter 2021 earnings released: EPS NT$0.32 (vs NT$0.61 in 1Q 2020)

OK Biotech Co., Ltd. (TPE:4155) Investors Should Think About This Before Buying It For Its Dividend

Calculating The Fair Value Of OK Biotech Co., Ltd. (TPE:4155)

Full year 2020 earnings released: EPS NT$1.56 (vs NT$1.71 in FY 2019)

OK Biotech (TPE:4155) Has A Pretty Healthy Balance Sheet

OK Biotech Co., Ltd., Annual General Meeting, May 27, 2021

Has OK Biotech (TPE:4155) Got What It Takes To Become A Multi-Bagger?

Is OK Biotech Co., Ltd.'s (TPE:4155) Recent Price Movement Underpinned By Its Weak Fundamentals?

A Look At OK Biotech's (TPE:4155) Share Price Returns

We Wouldn't Rely On OK Biotech's (TPE:4155) Statutory Earnings As A Guide

New 90-day low: NT$26.45

Consider This Before Buying OK Biotech Co., Ltd. (TPE:4155) For The 5.4% Dividend

New 90-day low: NT$26.55

Estimating The Intrinsic Value Of OK Biotech Co., Ltd. (TPE:4155)

New 90-day low: NT$27.85

Here's Why OK Biotech (TPE:4155) Can Manage Its Debt Responsibly

Should You Be Impressed By OK Biotech's (TPE:4155) Returns on Capital?

Third quarter 2020 earnings released: EPS NT$0.30

Revenue and earnings miss expectations

New 90-day high: NT$31.70

New 90-day low - NT$26.05

First half earnings released

OK Biotech Co., Ltd. has completed a Follow-on Equity Offering in the amount of TWD 34.268 million.

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane